LORELCO Drug Patent Profile

Which patents cover Lorelco, and when can generic versions of Lorelco launch?

Lorelco is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LORELCO is probucol. There are six drug master file entries for this compound. Additional details are available on the probucol profile page.

Summary for LORELCO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	4
Patent Applications:	3,959
DailyMed Link:	LORELCO at DailyMed

Recent Clinical Trials for LORELCO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Beijing Research Institute	Phase 1
Otsuka Beijing Research Institute	Phase 3
Otsuka Beijing Research Institute	N/A

See all LORELCO clinical trials

US Patents and Regulatory Information for LORELCO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988		DISCN	No	No

Expired US Patents for LORELCO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982

International Patents for LORELCO

See the table below for patents covering LORELCO around the world.

Country	Patent Number	Title	Estimated Expiration
France	8064
United Kingdom	1168193
Germany	1767443
Netherlands	6806010
Netherlands	154666

LORELCO Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Lipid-Lowering Drugs: A Focus on Lorelco

Introduction

Lipid-lowering drugs are a crucial segment of the pharmaceutical market, driven by the increasing prevalence of cardiovascular diseases globally. This article will delve into the market dynamics and financial trajectory of lipid-lowering drugs, with a specific focus on Lorelco (probucol), although it is important to note that Lorelco is no longer available in the U.S. market due to safety concerns.

Global Lipid-Lowering Drugs Market Overview

The global lipid-lowering drugs market was valued at USD 33.12 billion in 2023 and is projected to reach USD 46.58 billion by 2033, growing at a CAGR of 3.47% from 2024 to 2033[1].

Key Drivers of the Market

Rising Incidence of Cardiovascular Diseases

The increasing cases of cardiovascular diseases worldwide are a primary driver of the lipid-lowering drugs market. Factors such as sedentary lifestyles, unhealthy diets, obesity, and aging populations contribute to the rising demand for these drugs[1].

Advancements in Drug Technology

Advancements in lipid-lowering drugs, particularly the development of PCSK9 inhibitors, offer significant opportunities for market growth. These new classes of drugs are more effective in lowering cholesterol levels, attracting substantial investments in research and development[1].

Healthcare Infrastructure and Investments

Well-developed healthcare infrastructure and increasing investments in research and development activities in regions like North America further propel the market growth. These investments are crucial for the innovation and launch of new cholesterol-lowering drugs[1].

Market Segmentation

By Drug Type

The market is segmented into statins & combination, PCSK9 inhibitors, bile acid sequestrants, fibrates, cholesterol absorption inhibitors, and others. Statins remain a dominant segment due to their widespread use and effectiveness[1].

By Indication

The market is segmented by indication into hypercholesterolemia, coronary artery disease, and high triglycerides. Coronary artery disease is a significant segment, driven by its high prevalence and the critical role lipid-lowering drugs play in its management[1].

By Distribution Channel

Retail pharmacies dominate the market due to their higher preference and easy access. However, online pharmacies are expected to witness notable growth during the forecast period due to their convenience and accessibility[1].

Regional Outlook

North America

North America leads the lipid-lowering drugs market, driven by the high prevalence of cardiovascular diseases and a well-developed healthcare infrastructure. The sedentary lifestyle of the population in North American countries contributes to the higher demand for these drugs[1].

Asia Pacific

The Asia Pacific region is expected to witness the fastest growth due to the rising geriatric population and increasing adoption of sedentary lifestyles in countries like India and China. This region's growing pharmaceutical investments also drive market growth[1].

Lorelco (Probucol): Historical Context

Description and Use

Lorelco, or probucol, is an oral medication used to lower cholesterol levels in the blood. It was designed to prevent medical problems caused by cholesterol clogging blood vessels[5].

Market Withdrawal

Despite its intended use, probucol was voluntarily removed from the U.S. market in 1995 due to safety concerns. This withdrawal significantly impacted its market presence and financial trajectory[5].

Financial Trajectory of Lipid-Lowering Drugs

Revenue Growth

The lipid-lowering drugs market is expected to grow from USD 33.12 billion in 2023 to USD 46.58 billion by 2033. This growth is driven by increasing demand, advancements in drug technology, and rising investments in healthcare[1].

Revenue Distribution

The revenue is distributed across various segments, with statins and combination drugs being the largest contributors. The market is also influenced by the distribution channels, with retail pharmacies holding the largest share but online pharmacies growing rapidly[1].

Impact of Market Dynamics on Financial Performance

Research and Development Investments

Investments in research and development are crucial for the financial performance of pharmaceutical companies. The shift towards precision medicines and the development of new drug classes like PCSK9 inhibitors drive innovation and revenue growth[3].

Pricing Strategies

The pricing of lipid-lowering drugs is influenced by factors such as the size of the patient population and the presence of generic competition. Drugs targeting smaller patient populations, like some precision medicines, can command higher prices due to limited competition[3].

Distribution and Reimbursement System

The distribution and reimbursement system in the pharmaceutical industry is complex, involving multiple stakeholders such as manufacturers, wholesalers, pharmacies, and third-party payers. Financial flows and contractual relationships play a critical role in determining the profitability of lipid-lowering drugs[2].

Challenges and Opportunities

Safety Concerns and Regulatory Compliance

Safety concerns, as seen with Lorelco, can significantly impact a drug's market presence. Ensuring regulatory compliance and addressing safety issues are essential for maintaining market share and financial stability[5].

Generic Competition

The lack of generic competition in certain segments can provide long-term profitability for branded drugs. However, this also means that firms must continually innovate to maintain market position[3].

Key Takeaways

• The global lipid-lowering drugs market is driven by the rising incidence of cardiovascular diseases and advancements in drug technology.
• North America leads the market, while the Asia Pacific region is expected to witness the fastest growth.
• Retail pharmacies dominate the distribution channel, but online pharmacies are growing rapidly.
• Safety concerns and regulatory compliance are critical for a drug's financial trajectory.
• Continuous innovation and investment in research and development are essential for market growth.

FAQs

What is the projected growth rate of the global lipid-lowering drugs market from 2024 to 2033?

The global lipid-lowering drugs market is expected to grow at a CAGR of 3.47% from 2024 to 2033[1].

Why was Lorelco (probucol) removed from the U.S. market?

Lorelco was voluntarily removed from the U.S. market in 1995 due to safety concerns[5].

Which region is expected to witness the fastest growth in the lipid-lowering drugs market?

The Asia Pacific region is expected to witness the fastest growth in the lipid-lowering drugs market during the forecast period[1].

What are the primary drivers of the lipid-lowering drugs market?

The primary drivers include the rising incidence of cardiovascular diseases, advancements in drug technology, and increasing investments in healthcare[1].

How does the distribution channel impact the lipid-lowering drugs market?

Retail pharmacies currently dominate the market, but online pharmacies are expected to grow significantly due to their convenience and accessibility[1].

Cited Sources:

1. Precedence Research - Lipid-lowering Drugs Market Size to Hit USD 46.58 Bn by 2033[1].
2. Drug Channels - Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System[2].
3. National Bureau of Economic Research - The Economics of Drug Development: Pricing and Innovation in a Changing Market[3].
4. BMJ Open - Efficacy of probucol on cognitive function in Alzheimer's disease[4].
5. Mayo Clinic - Probucol (oral route)[5].